Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia

British Journal of Urology

Volumn 78, Issue 3, 1996, Pages 405-408

  Matzkin, H ^a   Barak, M ^a   Braf, Z ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Finasteride; Free total; Neoplasm; Prostate; Prostate specific antigen

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

EID: 0030438248     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.00143.x     Document Type: Article

References (15)

1. Oesterling JE. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 154: 907-23
2. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update. J Urol 1994: 152: 1358-62
3. Christensson A. Bjork T, Nilsson O, Lilja H. Serum prostatespecific antigen complexed to oc, antichymotripsin as an indicator of prostate cancer. J Urol 1991: 150: 100-10
4. Rittmaster RS. Finasteride. New Engl }Med 1994: 330: 120-5
5. Guess HA. Heyse JF. Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993: 22: 31-7
6. Guess HA. Heyse JF.Gormley GJ, Stoner E. Oesterling JE. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase clinical trial. Urol Clin North Am 1993: 20: 627-35
7. Gormley GJ. Stoner E. Bruskevitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. New Engl J Med 1992: 327: 1185-91
8. Stoner E and Members of the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994: 43: 284-94
9. Matzkin H. (Then J. Braf Z. Three years of treatment with a 5-alpha reductase inhibitor (Finasteride) in the treatment of benign prostatic hypertrophy. Harefuah 1993; 125: 453-6
10. Lilja H. Significance of different molecular forms of serum PSA. Urol Clin North Am 1993; 20: 681-6
11. Bjork T, Bjartell A, Lilja H, Abrahamson PA, di SantAgnese A. Occurrence of otj antichymptripsin in the prostate-specific antigen producing prostatic epithelium may be a pre-requisite for complex binding of PSA to ar ACT in blood. J Urol 1993; 149: 332A
12. Geller J. Effect of finasteride, a 5-alpha reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990; 71: 1552-5
13. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen:review of available data. J Urol 1996; 155: 3-9
14. Gormley GJ, Stoner E, Ng J, Guess HA, Cook T, Walsh PC. Effect of flnasteride on prostate-specific antigen density. Urology 1994; 43: 53-9
15. Presti JC, Fair WR, Andriole G et al. Multi-center, randomized double blind placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992; 148: 1201-4